(Bloomberg) — CVS Caremark Corp. (NYSE:CVS), the largest provider of prescription drugs in the U.S., posted first-quarter profit that fell short of estimates as cold weather — and a mild flu season — hurt sales. The company reaffirmed its 2014 forecast.
Earnings, excluding one-time items, of $1.02 a share missed by 2 cents the average of 21 analyst estimates compiled by Bloomberg. Full-year profit is still expected to be $4.36 to $4.50 a share, the the Woonsocket, R.I.-based company said in a statement today.
The severe winter weather kept consumers out of storefront pharmacies during the quarter, reducing sales of prescription drugs and consumer goods. CVS joined Express Scripts Holding Co., its biggest rival in the pharmacy benefit management business, in receiving a subpoena from the U.S. Attorney’s Office for the District of Rhode Island, CVS Chief Executive Officer Larry Merlo said.
The subpoena requested documents similar to those from “one of our competitors as it relates to fees and rebates,” Merlo said on a conference call with analysts. “We are cooperating fully on that matter.”
Express Scripts said earlier this week it was asked for information about its contractual arrangements with Pfizer Inc., Bayer EMD Serono and Biogen Idec Inc. regarding the medicines Betaseron, Rebif and Avonex.